Graft-specific immune tolerance is determined by residual antigenicity of xenogeneic extracellular matrix scaffolds.

ABSTRACT: Antigenicity remains the primary barrier towards expanding the use of unfixed xenogeneic biomaterials in clinical applications. An unfixed xenogeneic biomaterial devoid of antigenicity, with maintained structural and mechanical integrity, has potential to overcome the limitations of current clinically utilized glutaraldehyde-fixed xenogeneic biomaterials, such as heart valve bioprostheses. Unfortunately, the threshold level of residual antigenicity necessary to overcome graft-specific immune responses in unfixed xenogeneic tissue has yet to be determined. Furthermore, little information is known regarding the extent to which in vitro disruption of native ECM properties, resulting from decellularization or antigen removal procedures, are tolerated following in vivo implantation. This manusc

SUBMITTER: Dalgliesh AJ 

PROVIDER: S-EPMC6349227 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature